Cite

HARVARD Citation

    Kim, J. et al. (2022). A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019. Open forum infectious diseases. p. . [Online]. 
  
Back to record